Aptus Pharma share price, P/E, ROE & financials

As of 6 Nov 2026, Aptus Pharma trades at 100.2× trailing earnings, above the industry P/E of 36.7×. Sales and net profit grew 50% and 187% a year over 3 years, with ROCE of 29% and ROE of 32%. Debt is 0.43× equity. It is listed on an SME platform with a market cap of ₹797 Cr, ranked 2nd of 11 Medical Distribution companies by market cap; the shares rose 773% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Mar 2026.How we calculate this

past year

Open: ₹460.80
Day high: ₹469.60
Day low: ₹460.80
Prev. close: ₹460.75
Volume: 4K

Health check

2 good · 2 fair · 2 to check

ReturnsAhead
+772.6% over a year, better than 7 of 7 peers.
Price tagPricier
P/E 100.2 vs industry 36.7.
GrowthSteady
Sales +49.6%, profit +187.5% a year over 3 years.
ProfitabilityStrong
ROCE 29.3% vs peer median 4.4%.
Balance sheetFair
Debt 0.43× equity, interest covered 9.8×, Piotroski 4 of 9.
Red flags1 to check
P/E of 100.2 against an industry P/E of 36.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Medical Distribution

10 listed peers. Screen the industry

Small cap

₹797 Cr, #2 of 11 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Mar 2026: sales ₹81 Cr · profit ₹8 Cr

Market cap: ₹797 Cr; Small cap
P/E: 100.2; Industry 36.7
Price to book: 28.06; Peers 1.16
Dividend yield: 0.00%
ROE: 31.7%; Peers 6.7%
ROCE: 29.3%; Peers 4.4%
Debt to equity: 0.43; Debt ₹12 Cr
EPS (TTM): ₹4.64
OPM (TTM): 15.4%; Net margin 9.8%
Sales growth: +117.5%; Latest quarter vs a year ago
Profit growth: +60.1%; Latest quarter vs a year ago
Price to sales: 9.83; EV/EBITDA 65.2

Strengths

Return on equity of 31.7%.
Return on capital employed of 29.3%.
Quarterly profit up 60.1% on a year ago.
Quarterly sales up 117.5% on a year ago.

Risks to check

P/E of 100.2 against an industry P/E of 36.7.

Derived automatically from reported figures. Not a recommendation.

About Aptus Pharma

Aptus Pharma Limited engages in the marketing and distribution of finished pharmaceutical formulations. The company operates through four divisions: Aptus Pharma, Pioneer division, which includes marketing of acute therapies including general anti-infectives, pain management, antacids, and gastrointestinal drugs; Aptus CD Care, Cardiac Diabetic division, which includes marketing of chronic therapies, including antihypertensive, anti-diabetic, and…

Headquarters: Rajkot
Employees: 91
Sector: Healthcare
ISIN: INE15XJ01010
Website: aptus-pharma.com

Price range

52 weeks

₹57.20₹510.90

Today

₹460.80₹469.60

Avg volume (3M): 16K
1-year return: plus 772.6%
From 52-week high: minus 9.0%

Peers · Medical Distribution

Compare with peers Screen the whole industry

Company
ENTEROEntero Healthcare Solutions	1,900.40	plus 8.34%	8,279	66.0	4.90	11.3%	6.7%	4.4%	25.7%	–	0.00%	plus 62.4%
APPLAptus Pharma	465.00	plus 0.92%	797	100.2	28.06	29.3%	31.7%	15.4%	49.6%	187.5%	0.00%	plus 772.6%
ARVAYAArvaya Healthcare	111.00	minus 4.31%	576	–	–	1.4%	2.2%	0.0%	193.6%	–	0.00%	plus 143.1%
EVEXIAEvexia Lifecare	1.46	minus 3.31%	274	146.0	0.67	0.3%	0.3%	1.6%	16.6%	34.5%	0.00%	minus 15.2%
NOVELIXNovelix Pharmaceuticals	64.66	minus 4.91%	184	36.7	2.93	7.4%	8.0%	3.1%	354.8%	–	0.00%	plus 29.5%
AMWILLAmwill Health Care	44.00	plus 5.67%	88	7.8	1.06	15.5%	14.4%	14.1%	14.7%	54.2%	2.27%	minus 25.4%
CBPLChandra Bhagat Pharma	55.50	minus 4.31%	42	13.7	1.26	–	9.7%	2.5%	–	–	0.00%	plus 45.0%
WELCUREWelcure Drugs and Pharmaceuticals	0.18	minus 5.26%	22	–	0.23	−5.7%	−5.5%	−1.5%	–	–	0.00%	minus 62.7%
Median of 7 peers	–	−4.31%	184	36.7	1.16	4.4%	6.7%	2.5%	25.7%	44.3%	0.00%	29.5%

Quarterly results

Consolidated, ₹ crore · latest reported Mar 26

SalesSelect a row below to chart it

₹ Cr	Mar 25	Mar 26
	14.8	32.2
	11.9	27.7
	2.9	4.5
	19.4%	14.0%
	0.1	0.1
	0.4	0.3
	0.2	0.2
	2.4	4
	26.5%	28.6%
	1.8	2.9
	1.05	1.68

Jun 25, Sep 25, Dec 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +49.6%
Profit CAGR 3Y: +187.5%
EPS CAGR 3Y: +201.6%
ROE: 31.7%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
13.9	17.9	24.6	46.6
–	+28.5%	+37.5%	+89.7%
13.3	16.3	19.7	39.1
0.6	1.5	4.9	7.5
4.5%	8.7%	19.9%	16.0%
−0	−0.1	−0.1	0.1
0.1	0.2	0.3	0.7
0.2	0.2	0.3	0.4
0.3	1.1	4.2	6.4
34.2%	28.6%	26.1%	27.5%
0.2	0.8	3.1	4.6
–	+310.8%	+288.4%	+49.0%
0.11	0.47	1.81	3.11

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
0.3	0.3	5	6.9
0.7	1.5	2	16.5
2.2	5.3	10.4	7.2
3	3	4.6	13
6.2	10	21.9	43.5
0.5	0.6	1	2.7
–	–	0.1	–
–	1	1.1	5.4
0.5	0.9	5.2	1
5.2	7.5	14.6	34.4
6.2	10	21.9	43.5

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−0.2	−2.2	−1.8	−5.6
−0.4	−0.3	−0.5	−6.2
0.8	2.9	6.7	8.6
0.3	0.4	4.3	−3.2
−0.4	−0.3	−0.6	−2.2
−0.5	−2.5	−2.5	−7.8

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you